Browsing by Subject "424/85.4"
Now showing items 1-8 of 8
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2011-11-29)The invention relates to compositions and methods related to Toll-like receptor (TLR) polypeptides. In some embodiments, the invention relates to managing TLR3 related diseases. In further embodiments, the invention relates ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 2002-04-16)Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 1989-04-11)A biologically active interferon can be administered to an animal in conjunction with the administration of a vaccine to improve the vaccine efficiency and allow the use of a smaller vaccination dose. This procedure will ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 1999-06-08)Improved methods for administering an interferon (IFN) to a warm-blooded vertebrate are described. The methods employ oral administration of the IFN to the vertebrate in very low dosages, for example, 0.1 to 1.5 IU per ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-12-08)Autoimmune disorders are treated by the administration of human interferon, particularly IFN-α or IFN-β, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 1999-03-16)Hyperallergenic conditions are treated by the administration of interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 1991-05-28)Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of ...
-
(United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-10-20)Neoplastic diseases are treated by the administration of human interferon, particularly IFN-α, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and ...